Dicot's study drug has arrived in Sweden

Press release: Uppsala, May 17, 2023. In preparation for Dicot's phase 1 clinical trial, the study drug to be used has now been manufactured by Thermo Fisher Scientific and arrived in Sweden.

In February, the contract manufacturer Thermo Fisher Scientific began producing the study drug to be used when Dicot enters clinical trials with its potency drug candidate, which is planned for August this year. The manufacturing, done according to Good Manufacturing Practice, has now been completed and the study drug has arrived in Sweden.

Study drug with active substance as well as matching placebo have been manufactured, in accordance with the requirements for conducting a clinical phase 1 trial. Now Uppsala-based CTC AB – the contract research organization that will conduct the study – takes over the responsibility for the study drug, to prepare and dispense it for use in the clinical trial.

"It feels really good that this important piece of the puzzle is in place and that we have the pleasure of working with highly professional partners in our supply chain," says Elin Trampe, Dicot's CEO.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.